Tilray Brands (TLRY) Total Current Liabilities (2017 - 2026)
Tilray Brands' (TLRY) quarterly Total Current Liabilities came in at $358.4 million in Q2 2026, up 167.57% YoY from $133.9 million in Q2 2025, and up 39.15% on a QoQ basis from $257.5 million in Q1 2026.
Tilray Brands (TLRY) Total Current Liabilities (2017 - 2026) Analysis & Trends
Tilray Brands (TLRY) has 10 years of Total Current Liabilities data on file, last reported at $358.4 million in Q2 2026.
- Quarterly Total Current Liabilities rose 167.57% year-over-year to $358.4 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $358.4 million (up 167.57% YoY) and the FY2026 annual result came in at $358.4 million, up 167.57% from the prior year.
- Total Current Liabilities rose to $358.4 million in Q2 2026, from $257.5 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $537.3 million in Q3 2023 to a low of $123.8 million in Q1 2025.
- A 5-year average of $316.6 million and a median of $288.0 million in 2022 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2025 — Total Current Liabilities sank 62.38% — and 2026, when it surged 167.57%.
- Tracing TLRY's Total Current Liabilities over 5 years: stood at $426.5 million in 2022, then decreased by 7.39% to $395.0 million in 2023, then retreated by 29.49% to $278.5 million in 2024, then dropped by 6.9% to $259.3 million in 2025, then jumped by 38.2% to $358.4 million in 2026.
- The last three Total Current Liabilities figures came in at $358.4 million (Q2 2026), $257.5 million (Q1 2026), and $259.3 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 1.79 Bn |
| 10 | Tilray Brands | 513.87 Mn | 279.24 Mn | 90.52 Mn | 358.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 358.38 Mn |
| Feb 28, 2026 | 257.54 Mn |
| Nov 30, 2025 | 259.32 Mn |
| Aug 31, 2025 | 267.63 Mn |
| May 31, 2025 | 133.94 Mn |
| Feb 28, 2025 | 123.80 Mn |
| Nov 30, 2024 | 278.52 Mn |
| Aug 31, 2024 | 293.55 Mn |
| May 31, 2024 | 299.17 Mn |
| Feb 29, 2024 | 329.10 Mn |
| Nov 30, 2023 | 394.99 Mn |
| Aug 31, 2023 | 537.27 Mn |
| May 31, 2023 | 432.98 Mn |
| Feb 28, 2023 | 469.68 Mn |
| Nov 30, 2022 | 426.51 Mn |
| Aug 31, 2022 | 273.26 Mn |
| May 31, 2022 | 280.34 Mn |
| Feb 28, 2022 | 282.43 Mn |
| Nov 30, 2021 | 314.93 Mn |
| Aug 31, 2021 | 526.83 Mn |